These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29340326)

  • 21. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target.
    Pleniceanu O; Shukrun R; Omer D; Vax E; Kanter I; Dziedzic K; Pode-Shakked N; Mark-Daniei M; Pri-Chen S; Gnatek Y; Alfandary H; Varda-Bloom N; Bar-Lev DD; Bollag N; Shtainfeld R; Armon L; Urbach A; Kalisky T; Nagler A; Harari-Steinberg O; Arbiser JL; Dekel B
    EMBO Mol Med; 2017 Apr; 9(4):508-530. PubMed ID: 28275008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
    Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
    PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex.
    Yang HM; Choi HJ; Hong DP; Joo SY; Lee NE; Song JY; Choi YL; Lee J; Choi D; Kim B; Park HJ; Park JB; Kim SJ
    Exp Mol Pathol; 2014 Dec; 97(3):440-4. PubMed ID: 25281918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas.
    Swallow E; King S; Song J; Peeples M; Signorovitch JE; Liu Z; Prestifilippo J; Frost M; Kohrman M; Korf B; Krueger D; Sparagana S
    Urology; 2017 Jun; 104():110-114. PubMed ID: 28263820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tuberous sclerosis complex: Hamartin and tuberin expression in renal cysts and its discordant expression in renal neoplasms.
    Bonsib SM; Boils C; Gokden N; Grignon D; Gu X; Higgins JP; Leroy X; McKenney JK; Nasr SH; Phillips C; Sangoi AR; Wilson J; Zhang PL
    Pathol Res Pract; 2016 Nov; 212(11):972-979. PubMed ID: 27640314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical Conundrum: A Case of Giant Renal Angiomyolipoma Abutting Inferior Vena Cava With Haemorrhage.
    Sahu S; Vempati R; Mendpara V; Yadav M; Sayed Mushir Ali A; Vashyani A; Dinesh Eshwar M; Chauhan DR
    Cureus; 2022 Oct; 14(10):e30016. PubMed ID: 36381741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
    Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
    PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
    Siroky BJ; Yin H; Babcock JT; Lu L; Hellmann AR; Dixon BP; Quilliam LA; Bissler JJ
    Am J Physiol Renal Physiol; 2012 Sep; 303(6):F831-44. PubMed ID: 22791333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
    Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K
    Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms.
    Kenerson H; Folpe AL; Takayama TK; Yeung RS
    Hum Pathol; 2007 Sep; 38(9):1361-71. PubMed ID: 17521703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
    Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
    Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
    Kasner MT; Mick R; Jeschke GR; Carabasi M; Filicko-O'Hara J; Flomenberg N; Frey NV; Hexner EO; Luger SM; Loren AW; Mangan JK; Wagner JL; Weiss M; Carroll M; Perl AE
    Invest New Drugs; 2018 Aug; 36(4):657-666. PubMed ID: 29607465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term Clinical Morbidity in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex.
    Bissler J; Cappell K; Charles H; Song X; Liu Z; Prestifilippo J; Gregory C; Hulbert J
    Urology; 2016 Sep; 95():80-7. PubMed ID: 27132503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Giant bilateral renal angiomyolipomas and lymphangioleiomyomatosis presenting after two successive pregnancies successfully treated with surgery and rapamycin.
    Peces R; Cuesta-López E; Peces C; Selgas R
    ScientificWorldJournal; 2011; 11():2115-23. PubMed ID: 22125460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report.
    Tsai JD; Wei CC; Yang SH; Fan HC; Hsu CC; Tung MC; Tsai ML; Sheu JN
    Nephrology (Carlton); 2017 Dec; 22(12):1017-1022. PubMed ID: 27565896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.
    Brakemeier S; Bachmann F; Budde K
    Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
    Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
    J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.